News

The formation of alpha-synuclein aggregates in brain nerve cells (neurons) is thought to be one of the hallmarks of Parkinson disease. Researchers now have found that the activity of a single protein, called HYPE, may help halt alpha-synuclein accumulation and reduce its toxic outcomes, including neuronal death. These findings, “…

A molecule called anle138b was able to reduce toxic alpha-synuclein aggregates, or clumps, in the brain — a key event linked to Parkinson’s — and reverse motor symptoms associated with the disease in a novel Parkinson’s mouse model. The study, “Depopulation of dense α-synuclein aggregates is associated…

For 33 years, the Ride the Rockies cycling tour has lured thousands of cyclists and spectators globally to Colorado for 445 miles of strenuous biking that benefits area communities. This year, the June 9–15 tour will further its charitable impact by supporting organizations such as the Davis Phinney…

Using ultrasound coupled with the intravenous injection of microbubbles lessened brain damage in a mouse model of early Parkinson’s and may provide a noninvasive way to successfully deliver therapies into the brains of people with the disease, a study reports. A clinical trial with Alzheimer’s disease patients has been…

Data collected through Global Kinetics Corporation’s wearable device called Personal KinetiGraph (PKG) can help clinicians identify Parkinson’s patients who may benefit from deep-brain stimulation (DBS) or other device-assisted therapies. This finding was reported in the study, “The Use of Data from the Parkinson’s KinetiGraph…

A potential gene therapy for Parkinson’s disease associated with mutations in the GBA1 gene, PR001, will move into clinical testing in patients after the U.S. Food and Drug Administration (FDA) accepted an application for the therapy, Prevail Therapeutics announced. FDA acceptance of the company’s Investigational New…

The U.S. Food and Drug Administration (FDA) has approved a generic equivalent to Sinemet (carbidopa/levodopa) for the treatment of Parkinson’s disease, according to a press release. The oral therapy, produced by India-based Alembic Pharmaceuticals, will be available as extended-release tablets containing either 50 mg…

A single dose of Axovant’s gene therapy candidate AXO-Lenti-PD continues to improve motor function and has been well-tolerated after six months in two patients with advanced Parkinson’s disease, according to early results of an ongoing Phase 1/2 clinical trial. “We continue to be encouraged by the consistency of the…

Japanese researchers have reported that zonisamide — an antiparkinsonian medicine approved in Japan as a combination therapy with levodopa — may be associated with a lower risk of dementia, insomnia, and gastric ulcers in Parkinson’s disease, compared with other non-levodopa medicines. Their research was published in the…

With the aim of transforming training and education for Parkinson’s disease  and Lewy body dementia (LBD) caregivers and healthcare professionals, Embodied Labs has created a new virtual reality immersive learning lab. Embodied Labs allows caregivers and medical staff to embody a person with a specific condition, and…